Tech Company Financing Transactions
Abata Therapeutics Funding Round
Abata Therapeutics closed a $95 million Series A funding round on 6/24/2021. Backers included Third Rock Ventures, ElevateBio and Invus.
Transaction Overview
Company Name
Announced On
6/24/2021
Transaction Type
Venture Equity
Amount
$95,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Abata's autologous Treg cell therapies are engineered to express T cell receptors (TCRs) that recognize antigens present in tissue where an autoimmune response has been triggered. This enables Abata's Tregs to target the site of disease for a robust effect without imposing systemic immune suppression.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Samantha Singer
Chief Medical Officer
Richard Ransohoff
Chief Operating Officer
John Trzupek
Chief Scientific Officer
Andrea van Elsas
Chief Technical Officer
Stephen Sofen
Browse more venture capital transactions:
Prev: 6/24/2021: GoodTime venture capital transaction
Next: 6/24/2021: Drata venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs